New York, March 3, 2026, 09:45 EST — Regular session
- Arcus Biosciences shares slipped early Tuesday, giving back some ground after a steep rally on Monday.
- Leerink bumped its target up to $49. Traders now eye whether that change holds.
- Up next: a fireside chat set for March 9 at the Leerink Global Healthcare Conference.
Arcus Biosciences Inc slipped roughly 3.5% to $23.10 early Tuesday, pulling back after a strong rally the day before. Earlier, shares edged down around 0.9% ahead of the open.
The retreat is grabbing attention because RCUS has settled back into a “one-program” play, its shares rising or falling with every new development in the kidney-cancer narrative. That’s the setup: any update catches a reaction, sometimes a sharp one, and then the move can just as easily fizzle out.
This period lines up with a packed calendar of healthcare conferences and shifting biotech strategies, a time when investors push hard for precise timelines and straightforward funding. Quick-moving small caps? They often face scrutiny right out of the gate the next day.
Arcus shares jumped $3.57 on Monday, settling at $23.94 after closing at $20.37 last Friday. That’s a one-day rally of roughly 17.5%.
Leerink Partners bumped its price target on Arcus up to $49, from $36, sticking with its “outperform” call, a report noted Monday. Analysts use price targets as their best guess for where a stock might land in the next year. TipRanks
Arcus reported on Feb. 25 that its late-line kidney cancer drug casdatifan posted a median progression-free survival of 15.1 months. The company closed out 2025 with around $1.0 billion in cash, cash equivalents, and marketable securities. “We are focused on rapidly enrolling PEAK-1,” CEO Terry Rosen said in the release. Business Wire
Chief medical officer Richard Markus, in a Feb. 23 update, reported that patients on the 100mg tablet hit 15.1 months of progression-free survival, with confirmed responses seen in 45%. Progression-free survival tracks how long patients avoid worsening cancer.
Casdatifan takes aim at HIF-2α, the same cancer pathway Merck’s belzutifan (Welireg) already proved out in kidney cancer. The FDA cleared belzutifan for use in 2023 in adults with advanced renal cell carcinoma who’ve previously tried other treatments.
Dilution risk is also back in focus for traders. According to a recent SEC filing, Arcus has launched an at-the-market offering that could total as much as $200 million—meaning the company now has the option to sell shares directly into the market, tapping prevailing prices over time.
Biotech surges have a habit of petering out—maybe trial data misses, maybe enrollment slows, or risk appetite dries up. Once investors catch a whiff of potential equity raises on top of shaky clinical prospects, those momentum plays can unravel fast.
March 9 brings another key marker for investors: Arcus is set for a fireside chat at the Leerink Global Healthcare Conference, starting at 11:20 a.m. ET. Traders will be tuned in for any tweaks—trial timelines, hints about enrollment, or even a shift in funding signals all in play.
